At ASPHALION, we are proud to be the regulatory partner of the EU-funded project SPIOMET4HEALTH , working towards developing the first treatment specifically approved for #PCOS.
Last week, the project held its 4th General Assembly Meeting, where each partner presented the status and progress of their Work Packages (WPs).
As leaders of WP7: “Regulatory and Exploitation”, we presented an overview of the achievements to date and the ongoing tasks, just as the rest of our partners did for their respective WPs.
The project is progressing steadily — we are currently at Month 55 out of 69, including the 9-month extension granted to the project.
This time, our colleague Joan Cabellos represented ASPHALION at the meeting, sharing our progress and contributing to the collective discussion on next steps.
We are proud to collaborate with all partners in driving forward this important initiative, which brings us closer to providing innovative, effective solutions for people living with PCOS.
Need help for your HORIZON Europe projects? Contact us at: [email protected]
